PGEN
Precigen, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -5.1% ·
net new positions +6.2%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 910 | $7,453 | +1 | n/a |
| Q2 2026 | 80 | +1 | 77.32M | $440.58M | +8 | −7 |
| Q1 2026 | 82 | +6 | 77.19M | $298.23M | +8 | −2 |
| Q4 2025 | 75 | -2 | 85.66M | $358.05M | n/a | −2 |
| Q3 2025 | 16 | +1 | 41.97M | $138.07M | +2 | −1 |
| Q2 2025 | 12 | +2 | 40.00M | $56.80M | +2 | n/a |
| Q1 2025 | 7 | 0 | 18.74M | $27.92M | +1 | −1 |
| Q4 2024 | 7 | -3 | 18.78M | $21.04M | n/a | −3 |
| Q3 2024 | 9 | +1 | 17.66M | $16.73M | +1 | n/a |
| Q2 2024 | 8 | n/a | 6.84M | $10.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 12.15M | +9.0% | $39.97M | 0.0% | ▲ Add | 2 | SEC ↗ ×9 |
| 2 | The Vanguard Group ✦ (passive) | 8.94M | -1.4% | $29.42M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 3 | State Street Global Advisors ✦ (passive) | 4.49M | +48.2% | $14.77M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.85M | +2.7% | $12.67M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 2.74M | New | $9.02M | 0.0% | New | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 2.70M | +756.4% | $8.87M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 1.98M | n/a | $6.52M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | JPMorgan Chase ✦ | 1.52M | n/a | $5.00M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Adage Capital Partners ✦ | 846.00K | -92.5% | $2.78M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Millennium Management ✦ | 779.56K | +226.5% | $2.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 733.49K | n/a | $2.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Wellington Management ✦ | 522.18K | New | $1.72M | 0.0% | New | 1 | SEC ↗ ×3 |
| 13 | Marshall Wace ✦ | 411.79K | +11.6% | $1.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 116.66K | -65.1% | $383,818 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | AQR Capital Management ✦ | 106.46K | -9.5% | $350,257 | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 16 | T. Rowe Price ✦ | 79.56K | +15.5% | $262,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $9.02M | 0.0% |
| Wellington Management | $1.72M | 0.0% |
Exited
| Renaissance Technologies | $408,112 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 204 holders, 132.74M shares, $508.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 3.41K sh @ 7.23 · $24,662
Open-market sales (S)
Director · 185.00K sh · $1.38M
Officer · 15.34K sh · $115,065
Officer · 79.17K sh · $593,745
Officer · 34.66K sh · $259,935
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology